The National Institute of Neurological Disorders and Stroke (NINDS), the National Institute on Drug Abuse (NIDA), and the National Institute of Mental Health (NIMH) encourage grant applications for research on non-human lentiviral models of the neurological complications of AIDS. This announcement is supported by 2 grant funding mechanisms: R03 and R21.*
Neurological dysfunction is a devastating complication of HIV/AIDS, affecting more than 25 percent of chronically infected individuals. Symptoms include cognitive deficits, motor impairment, and peripheral neuropathies.
Areas of research interest include, but are not limited to: studies to define the pathogenic mechanisms of lentiviruses in the central nervous system (CNS) of animals temporally during the progression of disease; in vivo studies of host and viral factors affecting the penetration of lentiviruses and infected cells across the neuroprotective blood-brain barrier; use of non-human animal models to define and characterize novel markers associated with disease progression and response to therapeutic interventions; development of non-human animal models of peripheral neuropathy caused by lentiviral infection; use of lentiviral models for concurrent study of neurologic complications in animals repetitively exposed to substances of abuse, such as methamphetamine, opiates, cocaine, and marijuana, or withdrawn from such substances; and in vivo studies of glial-neuronal interactions in models of lentiviral infection and their complication by drugs of abuse.
For more information, potential applicants should contact Dr. Michael Nunn, Program Director, Neural Environment Cluster, NINDS, Neuroscience Center, 6001 Executive Boulevard, Room 2115, Bethesda, MD 20892; telephone: 301-496-1431; fax: 301-402-2060; e-mail: email@example.com.
*For a more detailed description of this announcement, please visit the NIH web site at: http://grants.nih.gov/grants/guide/pa-files/PAS-06-275.html (R03), or http://grants.nih.gov/grants/guide/pa-files/PAS-06-276.html (R21).